| Literature DB >> 27732632 |
Mariano Serrao1,2, Martina Rinaldi3, Alberto Ranavolo4, Francesco Lacquaniti5,6,7, Giovanni Martino5,6, Luca Leonardi1, Carmela Conte8, Tiwana Varrecchia3, Francesco Draicchio4, Gianluca Coppola9, Carlo Casali1, Francesco Pierelli1,10.
Abstract
BACKGROUND: Spastic gait is a key feature in patients with hereditary spastic paraparesis, but the gait characterization and the relationship between the gait impairment and clinical characteristics have not been investigated.Entities:
Mesh:
Year: 2016 PMID: 27732632 PMCID: PMC5061421 DOI: 10.1371/journal.pone.0164623
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patients’ characteristics.
| Patients | Gender | Heigth(cm) | Body Wt.(Kg) | Age(yr) | Diagnosis | Onset(yr) | Duration(yr) | SPRS | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ASHhip | ASHknee | Tot. | ||||||||
| p1 | M | 166 | 80 | 67 | __AR | 30 | 37 | 3 | 3 | 21 |
| p2 | F | 158 | 48 | 39 | __AD | 17 | 22 | 1 | 2 | 16 |
| p3 | F | 156 | 66 | 57 | SPG5 | 36 | 21 | 2 | 2 | 20 |
| p4 | M | 178 | 84 | 37 | SPG4 | — | — | 0 | 0 | 0 |
| p5 | F | 145 | 76 | 50 | __AD | 30 | 20 | 3 | 3 | 21 |
| p6 | F | 146 | 70 | 54 | __AD | 45 | 9 | 1 | 1 | 6 |
| p7 | F | 160 | 62 | 72 | __AD | 60 | 12 | 2 | 2 | 6 |
| p8 | F | 154 | 57 | 66 | SPG4 | 30 | 36 | 0 | 1 | 6 |
| p9 | M | 183 | 75 | 35 | __AD | 13 | 22 | 1 | 1 | 7 |
| p10 | M | 164 | 75 | 56 | SPG4 | 45 | 11 | 1 | 1 | 12 |
| p11 | F | 163 | 58 | 21 | SPG4 | 3 | 18 | 1 | 1 | 2 |
| p12 | M | 162 | 63 | 66 | SPG4 | 34 | 32 | 3 | 3 | 35 |
| p13 | F | 152 | 78 | 40 | SPG4 | — | — | 0 | 0 | 0 |
| p14 | M | 160 | 57 | 34 | SPG4 | 1–2 | 33 | 3 | 3 | 25 |
| p15 | M | 174 | 87 | 47 | SPG4 | 35 | 12 | 0 | 1 | 7 |
| p16 | M | 150 | 62 | 67 | __AD | 56 | 11 | 1 | 2 | 6 |
| p17 | M | 164 | 76 | 67 | __AR | 45 | 22 | 3 | 3 | 21 |
| p18 | M | 170 | 73 | 58 | SPG4 | 45 | 13 | 1 | 2 | 27 |
| p19 | M | 177 | 104 | 24 | SPG4 | 14 | 10 | 1 | 2 | 11 |
| p20 | M | 170 | 88 | 48 | __AR | 10 | 38 | 1 | 2 | 13 |
| p21 | M | 180 | 85 | 25 | __AD | 13 | 12 | 0 | 0 | 3 |
| p22 | M | 162 | 62 | 24 | __AR | 12 | 12 | 3 | 3 | 21 |
| p23 | M | 182 | 109 | 49 | SPG4 | 37 | 12 | 2 | 2 | 21 |
| p24 | F | 170 | 69 | 43 | SPG4 | 38 | 5 | 0 | 0 | 5 |
| p25 | F | 158 | 69 | 72 | SPG4 | 40 | 32 | 1 | 3 | 31 |
| p26 | F | 162 | 58 | 43 | SPG4 | 5 | 38 | 1 | 2 | 7 |
| p27 | F | 142 | 56 | 78 | SPG4 | 45 | 33 | 2 | 3 | 28 |
| p28 | M | 170 | 70 | 49 | __AD | 24 | 25 | 3 | 3 | 22 |
| p29 | F | 159 | 73 | 56 | __AR | 35 | 21 | 1 | 3 | 20 |
| P30 | F | 158 | 61 | 64 | SPG31 | 15 | 49 | 1 | 0 | 12 |
| p31 | F | 149 | 77 | 72 | SPG31 | 16 | 56 | 2 | 3 | 23 |
| p32 | M | 157 | 87 | 59 | __AR | 30 | 29 | 1 | 2 | 28 |
| p33 | F | 150 | 54 | 47 | SPG7 | 30 | 17 | 1 | 0 | 7 |
| p34 | M | 164 | 76 | 32 | __AR | 14 | 18 | 4 | 4 | 26 |
| p35 | M | 170 | 104 | 39 | __AD | 36 | 3 | 1 | 2 | 12 |
| p36 | F | 145 | 43 | 22 | __AD | 12 | 10 | 3 | 3 | 21 |
| p37 | M | 172 | 51 | 17 | SPG3A | 13 | 4 | 1 | 1 | 10 |
| p38 | M | 181 | 81 | 28 | SPG4 | 13 | 15 | 2 | 2 | 12 |
| p39 | M | 161 | 78 | 58 | SPG4 | 43 | 15 | 2 | 3 | 17 |
| p40 | M | 177 | 103 | 70 | SPG4 | 60 | 10 | 2 | 2 | 23 |
| p41 | M | 165 | 69 | 28 | __AD | 20 | 8 | 2 | 3 | 16 |
| p42 | M | 186 | 136 | 39 | SPG3A | 20 | 19 | 2 | 2 | 27 |
| p43 | F | 161 | 80 | 56 | SPG4 | 35 | 21 | 2 | 2 | 22 |
| p44 | M | 161 | 84 | 62 | SPG4 | 40 | 22 | 0 | 1 | 5 |
| p45 | M | 183 | 78 | 38 | SPG4 | 30 | 8 | 4 | 4 | 27 |
| p46 | M | 175 | 68 | 46 | SPG7 | 40 | 6 | 1 | 2 | 15 |
| p47 | M | 172 | 86 | 43 | SPG31 | 30 | 13 | 0 | 0 | 2 |
| p48 | F | 170 | 65 | 23 | __AR | 20 | 3 | 0 | 0 | 1 |
| p49 | M | 162 | 73 | 51 | __AD | 46 | 5 | 0 | 2 | 19 |
| p50 | F | 159 | 62 | 47 | SPG4 | 45 | 2 | 0 | 0 | 3 |
AD = autosomal dominant; AR = autosomal recessive; F = female; M = male; SPRS = Spastic Paraplegia Rating Scale; ASH = Ashworth scale of muscle spasticity; __ = molecular diagnosis still not available. The table lists the SPRS scores; higher scores indicate higher disease’s severity.
Fig 1Patients’ subgroups classification according to lower limb joint kinematic behavior.
The threshold of mean±1.5*SD of the joint RoMs of the control group is reported. Each patient joint RoM could be either reduced (below the threshold), increased (above the threshold) or close to the values of healthy controls. It is possible to note that the subgroups’ division corresponds also to the severity of the disease scored by SPRS scale (higher values of SPRS correspond to higher disease’s severity). Each triangle represents a patient with different colors according to the SPRS scores. Each circle represents a qualitative characterization of subgroup of patients with different color shades corresponding, in the three spatial dimensions, to the SPRS scores.
Time-distance, kinematic, kinetic and sEMG mean±SD data in patients and controls.
| Patients | Controls | |||
|---|---|---|---|---|
| Mean±SD | Mean±SD | P values | Cohen’s d | |
| Walking Speed [km/h] | 2.40±1.28 | 2.63±0.70 | 0.283 | 0.223 |
| Stance duration [% cycle] | 68.33±7.16 | 67.21±2.54 | 0.622 | 0.208 |
| Swing duration [% cycle] | 31.76±7.19 | 32.92±3.11 | 0.657 | 0.209 |
| 1st double support [% cycle] | 18.18±6.99 | 16.85±2.79 | 0.554 | 0.250 |
| 2nd double support [% cycle] | 19.07±9.14 | 16.91±3.34 | 0.434 | 0.314 |
| Cadence [steps/s] | 0.71±0.23 | 0.70±0.12 | 0.120 | 0.055 |
| Step length [% limb length] | ||||
| Step width [% limb length] | ||||
| Hip [°] | 35.10±6.78 | 34.96±4.63 | 0.905 | 0.024 |
| Knee [°] | ||||
| Ankle [°] | ||||
| Trunk lateral bending [°] | ||||
| Trunk flexion-extension [°] | ||||
| Trunk rotation [°] | ||||
| Pelvis obliquity [°] | 6.09±2.28 | 5.16±1.56 | 0.298 | 0.476 |
| Pelvis tilt [°] | 89.14±31.50 | 90.29±28.44 | 0.931 | 0.038 |
| Pelvis rotation [°] | ||||
| AI1stDS_Hip | 8.24±3.52 | 10.36±2.54 | 0.568 | 0.691 |
| AI2ndDS_Hip | 2.93±2.91 | 2.24±1.71 | 0.348 | 0.289 |
| AI1st_Knee | ||||
| AI2nd_Knee | 2.14±3.92 | 1.05±1.91 | 0.642 | 0.353 |
| AI1stDS_Ankle | 0.91±3.31 | 0.98±2.09 | 0.917 | 0.025 |
| AIMidStance_Ankle | 27.55±8.07 | 28.22±5.19 | 0.063 | 0.099 |
| AI2ndDS_Ankle | 8.63±5.22 | 7.03±3.07 | 0.716 | 0.374 |
| MSArea | 45.98±17.43 | 41.64±14.48 | 0.332 | 0.271 |
| MSPeak1 [N*m/Kg] | 1.09±0.34 | 1.02±0.41 | 0.324 | 0.186 |
| MSPeak2 [N*m/Kg] | 0.92±0.39 | 0.86±0.29 | 0.526 | 0.175 |
| TMCfArea_Ankle | ||||
| TMCfArea_Knee | 19.12±7.62 | 16.62±4.41 | 0.380 | 0.402 |
Bold type indicates significant differences between patients and controls. Cohen’s d values indicate the effect size for the comparison between the two means ("small" if d = 0.2, "medium" if d = 0.5, "large" if d = 0.8).
Fig 2Time-distance and joint and trunk kinematic parameters in HSP subgroups.
(A) Mean values (±SD) of time distance parameters. (B) (B) Mean (with SDs in light colors) kinematic plot of joint angular displacements during the gait cycle. (C) Mean values (±SD) of range of angular motion (RoM). Mean values of healthy controls for both time-distance and kinematic parameters, are reported in each bar graph (dotted line) and plot (black line). Asterisks indicate significant differences among the three subgroups at post hoc analysis (* p<0.05, ** p<0.001).
Fig 3Joint kinetic and muscles parameters in HSP subgroups.
(A) Mean (with SDs in light colors) kinetic plot of joint moments (hip, knee and ankle) and support moment. The patterns are normalized to body weight and plotted vs. normalized stance. (B) Mean values (±SD) of kinetic parameters. (C) Mean TMCfArea (±SD) calculated for ankle and knee muscles (TMCfArea_Ankle and TMCfArea_Knee). (D) Mean (with SDs in light colors) plot of co-activation of ankle and knee joint antagonist muscles during the gait cycle. Mean values of healthy controls for kinetic and muscles parameters are reported in each bar graph (dotted line) and plot (black line). Asterisks indicate significant differences among the three subgroups at post hoc analysis (* p<0.05).